Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.74% | 27.46% | 10.10% | 13.20% | 13.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.99% | 30.49% | 5.57% | -4.07% | 2.01% |
| Operating Income | -43.99% | -30.49% | -5.57% | 4.07% | -2.01% |
| Income Before Tax | -82.07% | -570.28% | 34.46% | 27.59% | 32.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.07% | -570.28% | 34.46% | 27.59% | 32.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.07% | -570.28% | 34.46% | 27.59% | 32.22% |
| EBIT | -43.99% | -30.49% | -5.57% | 4.07% | -2.01% |
| EBITDA | -44.35% | -30.81% | -5.87% | 3.58% | -3.26% |
| EPS Basic | -30.58% | -392.16% | 47.85% | 31.22% | 35.66% |
| Normalized Basic EPS | -30.66% | -391.91% | 47.90% | 31.22% | 35.81% |
| EPS Diluted | -30.58% | -392.16% | 47.85% | 31.22% | 36.47% |
| Normalized Diluted EPS | -30.66% | -391.91% | 47.90% | 31.22% | 35.81% |
| Average Basic Shares Outstanding | 39.37% | 36.20% | 25.71% | 5.33% | 5.34% |
| Average Diluted Shares Outstanding | 39.37% | 36.20% | 25.71% | 5.33% | 5.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |